Genentech’s trastuzumab-DM1 IND submission to the FDA has triggered a $2 million milestone payment to ImmunoGen. Trastuzumab-DM1 comprises ImmunoGen’s cell-killing agent, DM1, linked to Genentech’s therapeutic antibody, trastuzumab, which targets overexpression of the HER2 protein. “We are delighted to announce this milestone in our collaboration with Genentech,” said Mitchel Sayare, chairman and chief executive officer. “Genentech was the first company t...